Barings Corporate Investors (MCI) Competitors

Abrdn Life Sciences Investors (NYSE:HQL) and Barings Corporate Investors (NYSE:MCI) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Does the media favor HQL or MCI?

In the previous week, Abrdn Life Sciences Investors had 7 more articles in the media than Barings Corporate Investors. MarketBeat recorded 11 mentions for Abrdn Life Sciences Investors and 4 mentions for Barings Corporate Investors. Barings Corporate Investors' average media sentiment score of 1.29 beat Abrdn Life Sciences Investors' score of -0.07 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abrdn Life Sciences Investors	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Barings Corporate Investors	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is HQL or MCI a better dividend stock?

Abrdn Life Sciences Investors pays an annual dividend of $1.33 per share and has a dividend yield of 9.3%. Barings Corporate Investors pays an annual dividend of $1.42 per share and has a dividend yield of 8.1%. Barings Corporate Investors has increased its dividend for 2 consecutive years.

Is HQL or MCI more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Abrdn Life Sciences Investors	N/A	N/A	N/A
Barings Corporate Investors	N/A	N/A	N/A

Which has preferable valuation & earnings, HQL or MCI?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A
Barings Corporate Investors	N/A	N/A	N/A	N/A	N/A

Does the MarketBeat Community favor HQL or MCI?

Barings Corporate Investors received 138 more outperform votes than Abrdn Life Sciences Investors when rated by MarketBeat users. Likewise, 75.65% of users gave Barings Corporate Investors an outperform vote while only 68.35% of users gave Abrdn Life Sciences Investors an outperform vote.

Company	Underperform	Outperform
Abrdn Life Sciences Investors	Outperform Votes 95 68.35%	Underperform Votes 44 31.65%
Barings Corporate Investors	Outperform Votes 233 75.65%	Underperform Votes 75 24.35%

Do analysts rate HQL or MCI?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abrdn Life Sciences Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Barings Corporate Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more volatility and risk, HQL or MCI?

Abrdn Life Sciences Investors has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Barings Corporate Investors has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of HQL or MCI?

32.2% of Abrdn Life Sciences Investors shares are owned by institutional investors. 10.1% of Abrdn Life Sciences Investors shares are owned by insiders. Comparatively, 1.1% of Barings Corporate Investors shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Abrdn Life Sciences Investors beats Barings Corporate Investors on 6 of the 9 factors compared between the two stocks.